Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Orit Gutfeld
27 années d'expérience
La clinique est certifiée :
| Israël | Turquie | Espagne | |
| Halcyon | - | de $5,400 | - |
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Le Dr Orit Gutfeld est une oncologue spécialisée dans les cancers ORL, avec plus de 30 ans d'expérience clinique.
Le professeur Dan Fliss est un oncologue expérimenté, spécialiste du cancer du nasopharynx au centre médical Sourasky (Ichilov).
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.
Modern Israeli oncology centers report survival rates exceeding 80% for nonmetastatic nasopharyngeal carcinoma. Pediatric cases show high resilience with approximately 88% long-term survival. Success relies on advanced diagnostic protocols. These include PET-CT imaging and Epstein-Barr virus DNA monitoring to track disease progression.
Bookimed Expert Insight: Data from major Israeli hubs like Sheba and Sourasky shows a shift toward high-volume specialized care. Sheba serves over 2 million patients annually. This massive volume allows surgeons to maintain peak proficiency. We see clinics like Sourasky employing over 2,200 doctors. This depth of expertise often correlates with their reported 90% oncology success rate.
Patient Consensus: Patients emphasize the need for regular PSMA PET scans to detect issues standard imaging might miss. Many note that early detection of stage 1 symptoms significantly improves long-term outlooks.
Standard nasopharyngeal cancer treatment in Israel utilizes Intensity-Modulated Radiation Therapy (IMRT) or Volumetric-Modulated Arc Therapy (VMAT). Clinicians typically deliver 45 to 70 Gray (Gy). Standard fractionation involves daily 1.8 to 2 Gy doses over five to eight weeks. These methods optimize tumor destruction while shielding healthy tissue.
Bookimed Expert Insight: Israel's research centers like Sheba Medical Center often utilize Simultaneous-Integrated Boost (SIB). This technique delivers different dose levels to various tumor areas in one session. Our data shows this may shorten total treatment time compared to historical protocols. High-volume centers like Sourasky, serving over 400,000 patients, use these refinements to maintain a 90% oncology success rate.
Patient Consensus: Patients emphasize the value of early swallowing assessments and proactive salivary stimulators. Many recommend asking for a mid-treatment adaptive plan to handle physical changes like weight loss during the grueling therapy schedule.
Israeli oncologists use evidence-based regimens following National Comprehensive Cancer Network guidelines. They prescribe cisplatin-based concurrent chemoradiotherapy alongside intensity-modulated radiation therapy. High-risk cases often receive gemcitabine or docetaxel during induction. Immunotherapy trials investigate PD-1 inhibitors for advanced stages within these leading medical centers.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center and Hadassah Hospital show a pattern of high-volume specialty. These clinics manage over 15,000 to 20,000 oncology patients annually. This volume allows multidisciplinary teams to refine dosing for non-keratinizing NPC subtypes common in the region. Their research-driven approach often provides earlier access to immunotherapy agents compared to standard regional clinics.
Patient Consensus: Patients often highlight the importance of the multidisciplinary team approach in Israel. They note that having radiation and medical oncologists coordinate closely helps manage side effects better.
Israel ensures accurate TNM staging through high-definition diagnostic imaging and multidisciplinary pathology reviews. Clinics use PET/CT scans and sinus CTs to detect microscopic spread. Specialists follow international AJCC protocols to classify tumor size, lymph node involvement, and metastasis before designing personalized treatment plans.
Bookimed Expert Insight: A major advantage in Israel is the density of top-ranked experts. Sheba Medical Center features over 200 Forbes-listed doctors. This concentration of expertise allows for secondary pathology reviews that frequently refine the initial stage. At Sourasky Medical Center, clinicians report a 90% average success rate in oncology partly due to these precise diagnostic standards.
Patient Consensus: Patients note the speed of Israeli diagnostics is impressive. Many report completing the entire staging workup within 4 days at private centers. They also value the thorough explanations provided by specialists like Dr. Orit Gutfeld during the initial planning phase.
Intensity-modulated proton therapy (IMPT) is an advanced alternative to photon-based IMRT for treating nasopharyngeal cancer in Israel. Specialists choose IMPT to spare critical organs like the brainstem and optic nerves from exit doses. This precision significantly reduces side effects like dry mouth and swallowing difficulties.
Bookimed Expert Insight: While IMRT is widely accessible, Israel's leading centers like Sheba Medical Center integrate AI and digital imaging to enhance treatment planning. Data shows that for nasopharyngeal cases, selecting a facility with multidisciplinary support is vital. For example, Dr. Raanan Berger at Sheba combines radiotherapy with molecular research to personalize care. Patients should prioritize clinics with Forbes-ranked specialists, as expertise in complex anatomy often outweighs the specific technology type for long-term survival.
Patient Consensus: Patients emphasize the importance of requesting side-by-side dosimetry plans to compare radiation doses to healthy organs. Many note that choosing advanced therapy significantly lowered their need for feeding tubes and reduced hearing loss.
International patients typically stay in Israel for 6 to 12 weeks during nasopharyngeal chemoradiation. This period covers daily radiotherapy and concurrent chemotherapy cycles. Specialists like Dr. Orit Gutfeld at Sourasky Medical Center oversee these regimens, which usually include a post-treatment recovery window of 1 to 4 weeks.
Bookimed Expert Insight: Patient volume data highlights why Israel is a preferred destination, with Sheba Medical Center alone serving 2,000,000 patients annually. Large multidisciplinary centers are better equipped to handle the coordination between oncology and ENT departments. For example, Dr. Dan Fliss at Sourasky holds titles in both fields. This dual expertise is crucial for managing the complex side effects specific to nasopharyngeal treatment during long-term stays.
Patient Consensus: Patients note that severe mouth sores often require staying 2 extra weeks beyond the initial plan. Many experts recommend booking flexible housing near the clinic and arranging telemedicine for early follow-ups to avoid frequent travel.
Leading Israeli hospitals for nasopharyngeal cancer include Sheba Medical Center, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. These centers use multidisciplinary tumor boards to coordinate complex care. Teams combine radiation oncology, ENT surgery, and medical oncology to create personalized protocols for every patient.
Bookimed Expert Insight: While most major Israeli centers provide comprehensive care, the volume differences are a key quality signal. Sheba Medical Center treats over 2 million patients annually and is ranked 7th worldwide by Newsweek. This massive volume allows their multidisciplinary boards to see rare nasopharyngeal cases more frequently than smaller private facilities. If your case involves complex skull base involvement, prioritize centers like Sheba or Sourasky. Their teams include neurosurgeons specifically for these advanced surgical boundaries.
Patient Consensus: Patients note it is important to verify which specialists will sit on your specific tumor board. They value how these meetings act as a second set of eyes to prevent diagnostic errors.